In its 2025-2026 budget, the Québec government introduced the Research, Innovation and Commercialization Tax Credit (CRIC), presented as a structuring measure to support innovation.
While the stated aim is to simplify and improve support for research, innovation and commercialization, this reform raises a number of concerns, particularly for SMEs in the life sciences and health technologies, as well as other innovative sectors.
A critical analysis of the new tax incentive regime for innovation
In this position paper, BIOQuébec examines the potential impacts of the CRIC, highlighting the effects on young innovative companies. The new regime risks weakening these R&D-intensive companies, for whom the tax credit is a decisive financial lever.
For a tax measure better adapted to the needs of innovative SMEs
BIOQuébec formulates concrete recommendations to ensure that the CRIC takes into account the sectoral specificities and business models of innovative SMEs. Effective tax support cannot be one-size-fits-all: it must be adapted to the diversity of the companies it aims to propel forward.
📄 Read the full statement to discover our analysis and recommendations.
This document is available in French only.
